Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT05467891 2026-02-27

RaPhLRR

Phase 2 Recruiting

200 enrolled

Breast

Locoregional Recurrence

NCT06179303 2026-02-27

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Phase 2 Recruiting

60 enrolled

Breast

Anatomic Stage III Breast Cancer AJCC v8

NCT06507618 2026-02-24

POWER II

Phase 3 Recruiting

354 enrolled

Breast

Breast Neoplasms

NCT06905301 2026-02-20

IMPULSE

Recruiting

240 enrolled

Breast

Breast Neoplasms

NCT07019363 2026-01-21

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)

Phase 3 Recruiting

1,903 enrolled

Breast

Breast Neoplasms

NCT05501704 2026-01-07

ETHAN - ET for Male BC

Phase 2 Recruiting

60 enrolled

Breast

Breast Neoplasms, Male

Clinical Trials

RAMP 301

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

ELEGANCE

OPERA-01

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

DEBRA

PIKALO-1

RaPhLRR

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

POWER II

IMPULSE

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)

ETHAN - ET for Male BC